JP6902045B2 - ピリミジンおよびそのバリアント、ならびにそのための使用 - Google Patents
ピリミジンおよびそのバリアント、ならびにそのための使用 Download PDFInfo
- Publication number
- JP6902045B2 JP6902045B2 JP2018549444A JP2018549444A JP6902045B2 JP 6902045 B2 JP6902045 B2 JP 6902045B2 JP 2018549444 A JP2018549444 A JP 2018549444A JP 2018549444 A JP2018549444 A JP 2018549444A JP 6902045 B2 JP6902045 B2 JP 6902045B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- mmol
- mixture
- formula
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)c(cc(cc1)OC)c1Sc1cnc(N)nc1N* Chemical compound CC(C)c(cc(cc1)OC)c1Sc1cnc(N)nc1N* 0.000 description 3
- CTJOZPFWVUXWIX-UHFFFAOYSA-N CC(C)c(c(Sc1c(N)nc(N)nc1)c1)cc(OC)c1C#C[Si](C)(C)C Chemical compound CC(C)c(c(Sc1c(N)nc(N)nc1)c1)cc(OC)c1C#C[Si](C)(C)C CTJOZPFWVUXWIX-UHFFFAOYSA-N 0.000 description 1
- HQGQGVOZAWVQAN-UHFFFAOYSA-N CC(C)c(c(Sc1c[nH]nc1N)c1)cc(OC)c1C#C Chemical compound CC(C)c(c(Sc1c[nH]nc1N)c1)cc(OC)c1C#C HQGQGVOZAWVQAN-UHFFFAOYSA-N 0.000 description 1
- DIVZAOOBIBOFQE-UHFFFAOYSA-N CC(C)c(c(Sc1cnc(N)nc1N)c1)cc(OC)c1Br Chemical compound CC(C)c(c(Sc1cnc(N)nc1N)c1)cc(OC)c1Br DIVZAOOBIBOFQE-UHFFFAOYSA-N 0.000 description 1
- DLRDJUCQPGETIR-UHFFFAOYSA-N CC(C)c(cc(c(I)c1)OC)c1Sc1c[nH]nc1N Chemical compound CC(C)c(cc(c(I)c1)OC)c1Sc1c[nH]nc1N DLRDJUCQPGETIR-UHFFFAOYSA-N 0.000 description 1
- CNLREBAATZJHJW-UHFFFAOYSA-N CC(C)c(cc(c(OC)c1)OC)c1S(c1cnc(N)nc1N)=O Chemical compound CC(C)c(cc(c(OC)c1)OC)c1S(c1cnc(N)nc1N)=O CNLREBAATZJHJW-UHFFFAOYSA-N 0.000 description 1
- IWPHXSVEEYGWPM-UHFFFAOYSA-N CC(C)c(nc(c(I)c1)OC)c1Oc1c(N)nc(N)nc1 Chemical compound CC(C)c(nc(c(I)c1)OC)c1Oc1c(N)nc(N)nc1 IWPHXSVEEYGWPM-UHFFFAOYSA-N 0.000 description 1
- ZGDYNXRQVWHHOF-UHFFFAOYSA-N CCc(c(Sc1cnc(N)nc1N)c1)cc(OC)c1S(C)(=O)=O Chemical compound CCc(c(Sc1cnc(N)nc1N)c1)cc(OC)c1S(C)(=O)=O ZGDYNXRQVWHHOF-UHFFFAOYSA-N 0.000 description 1
- KMRNEFKOGMYHFM-UHFFFAOYSA-N CCc(cc(cc1)OC)c1Sc1cnc(N)nc1N Chemical compound CCc(cc(cc1)OC)c1Sc1cnc(N)nc1N KMRNEFKOGMYHFM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662313334P | 2016-03-25 | 2016-03-25 | |
| US62/313,334 | 2016-03-25 | ||
| PCT/US2017/023126 WO2017165255A1 (en) | 2016-03-25 | 2017-03-20 | Pyrimidines and variants thereof, and uses therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510025A JP2019510025A (ja) | 2019-04-11 |
| JP2019510025A5 JP2019510025A5 (enExample) | 2020-04-09 |
| JP6902045B2 true JP6902045B2 (ja) | 2021-07-14 |
Family
ID=59900805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549444A Active JP6902045B2 (ja) | 2016-03-25 | 2017-03-20 | ピリミジンおよびそのバリアント、ならびにそのための使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10662162B2 (enExample) |
| EP (1) | EP3433258B1 (enExample) |
| JP (1) | JP6902045B2 (enExample) |
| KR (1) | KR102377805B1 (enExample) |
| CN (1) | CN108779119B (enExample) |
| AU (1) | AU2017237929B2 (enExample) |
| CA (1) | CA3018180C (enExample) |
| MA (1) | MA44489A (enExample) |
| MX (1) | MX384368B (enExample) |
| RU (1) | RU2760733C2 (enExample) |
| WO (1) | WO2017165255A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10822311B2 (en) | 2016-03-14 | 2020-11-03 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
| WO2017165255A1 (en) * | 2016-03-25 | 2017-09-28 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
| WO2018116139A1 (en) | 2016-12-19 | 2018-06-28 | Novartis Ag | New picolinic acid derivatives and their use as intermediates |
| JP6934945B2 (ja) * | 2016-12-20 | 2021-09-15 | アファレント ファーマシューティカルズ インコーポレイテッド | Ｐ２ｘ３アンタゴニストの結晶塩および多形 |
| CA3076680A1 (en) * | 2017-11-01 | 2019-05-09 | Beijing Tide Pharmaceutical Co., Ltd. | P2x3 and/or p2x2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof |
| CN107778255B (zh) * | 2017-11-16 | 2019-10-25 | 山东大学 | 一种二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 |
| CN114007620B (zh) * | 2019-04-30 | 2024-08-06 | 北京泰德制药股份有限公司 | 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法 |
| MX2021013338A (es) * | 2019-04-30 | 2022-01-24 | Beijing Tide Pharmaceutical Co Ltd | Método para tratar la tos usando un compuesto de diaminopirimidina. |
| SG11202111907UA (en) * | 2019-04-30 | 2021-11-29 | Beijing Tide Pharmaceutical Co Ltd | Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof |
| EP3981765A4 (en) * | 2019-06-06 | 2023-05-31 | Beijing Tide Pharmaceutical Co., Ltd. | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION CONTAINING IT AND THEIR USE |
| CN120058573A (zh) * | 2025-04-29 | 2025-05-30 | 潍坊学院 | 一种1-三溴甲基磺酰基萘及其衍生物的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2953567A (en) * | 1956-11-23 | 1960-09-20 | Burroughs Wellcome Co | 5-phenylmercaptopyrimidines and method |
| CA2369945A1 (en) * | 1999-04-06 | 2000-10-12 | James L. Kelley | Neurotrophic thio substituted pyrimidines |
| CA2432799C (en) * | 2000-12-21 | 2008-08-19 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| PL1725540T3 (pl) * | 2004-03-05 | 2013-02-28 | Hoffmann La Roche | Diaminopirymidyny jako antagoniści p2x3 i p2x2/3 |
| JP4850911B2 (ja) * | 2005-09-01 | 2012-01-11 | エフ．ホフマン−ラ ロシュ アーゲー | Ｐ２ｘ３およびｐ２ｘ２／３モジュレーターとしてのジアミノピリミジン |
| JP4850912B2 (ja) * | 2005-09-01 | 2012-01-11 | エフ．ホフマン−ラ ロシュ アーゲー | Ｐ２ｘ３およびｐ３ｘ２／３モジュレーターとしてのジアミノピリミジン |
| KR101012926B1 (ko) * | 2005-09-01 | 2011-02-09 | 에프. 호프만-라 로슈 아게 | Ｐ2ｘ3 및 ｐ2ｘ2/3 조정자로서의 다이아미노피리미딘 |
| CN101300235B (zh) * | 2005-09-01 | 2011-12-07 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物 |
| SI2343281T1 (sl) * | 2006-10-04 | 2014-06-30 | F. Hoffmann-La Roche Ag | Postopek za sintezo fenoksi diaminopirimidinskih derivatov |
| WO2008104472A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof |
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| CN101842359A (zh) * | 2007-10-31 | 2010-09-22 | 日产化学工业株式会社 | 哒嗪酮化合物和p2x7受体抑制剂 |
| GB2471713A (en) | 2009-07-08 | 2011-01-12 | Univ Greenwich | 1,2,4-triazine derivatives and their use as sodium channel blockers |
| TWI637949B (zh) * | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| MX367657B (es) * | 2013-08-23 | 2019-08-30 | Afferent Pharmaceuticals Inc | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica. |
| US10195198B2 (en) * | 2014-07-03 | 2019-02-05 | Afferent Pharmaceuticals, Inc. | Methods and compositions for treating diseases and conditions |
| US10822311B2 (en) * | 2016-03-14 | 2020-11-03 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
| WO2017165255A1 (en) | 2016-03-25 | 2017-09-28 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
-
2017
- 2017-03-20 WO PCT/US2017/023126 patent/WO2017165255A1/en not_active Ceased
- 2017-03-20 CN CN201780019534.0A patent/CN108779119B/zh active Active
- 2017-03-20 RU RU2018137032A patent/RU2760733C2/ru active
- 2017-03-20 MA MA044489A patent/MA44489A/fr unknown
- 2017-03-20 CA CA3018180A patent/CA3018180C/en active Active
- 2017-03-20 MX MX2018011622A patent/MX384368B/es unknown
- 2017-03-20 EP EP17770880.7A patent/EP3433258B1/en active Active
- 2017-03-20 AU AU2017237929A patent/AU2017237929B2/en active Active
- 2017-03-20 US US16/080,840 patent/US10662162B2/en active Active
- 2017-03-20 KR KR1020187029805A patent/KR102377805B1/ko active Active
- 2017-03-20 JP JP2018549444A patent/JP6902045B2/ja active Active
-
2020
- 2020-04-13 US US16/846,452 patent/US11230532B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180128015A (ko) | 2018-11-30 |
| WO2017165255A1 (en) | 2017-09-28 |
| CN108779119A (zh) | 2018-11-09 |
| RU2760733C2 (ru) | 2021-11-30 |
| MX2018011622A (es) | 2019-03-28 |
| US10662162B2 (en) | 2020-05-26 |
| MA44489A (fr) | 2019-01-30 |
| EP3433258A1 (en) | 2019-01-30 |
| MX384368B (es) | 2025-03-14 |
| RU2018137032A (ru) | 2020-04-27 |
| CA3018180C (en) | 2024-02-20 |
| JP2019510025A (ja) | 2019-04-11 |
| US11230532B2 (en) | 2022-01-25 |
| US20200239421A1 (en) | 2020-07-30 |
| RU2018137032A3 (enExample) | 2020-05-22 |
| KR102377805B1 (ko) | 2022-03-22 |
| CN108779119B (zh) | 2022-02-08 |
| EP3433258A4 (en) | 2019-10-30 |
| EP3433258B1 (en) | 2023-07-19 |
| BR112018069105A2 (pt) | 2019-01-29 |
| AU2017237929B2 (en) | 2021-04-15 |
| AU2017237929A1 (en) | 2018-09-13 |
| US20190055202A1 (en) | 2019-02-21 |
| CA3018180A1 (en) | 2017-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6902045B2 (ja) | ピリミジンおよびそのバリアント、ならびにそのための使用 | |
| JP6968810B2 (ja) | ピリミジンおよびそのバリアント、ならびにそのための使用 | |
| EP2183224B1 (en) | 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis | |
| CN114945566A (zh) | 作为钠通道调节剂的取代四氢呋喃 | |
| US9227951B2 (en) | Substituted hydroxamic acids and uses thereof | |
| KR20150128722A (ko) | 카텝신 c의 억제제로서 치환된 2-아자-바이사이클로[2.2.1]헵탄-3-카복실산(벤질-시아노-메틸)-아미드 | |
| JP6180643B2 (ja) | 新規フタラジノン誘導体及びその製造方法「Ａ ｎｏｖｅｌ ｐｈｔａｌａｚｉｎｏｎｅ ｄｅｒｉｖａｔｉｖｅｓ ａｎｄ ｍａｎｕｆａｃｔｕｒｉｎｇ ｐｒｏｃｅｓｓ ｔｈｅｒｅｏｆ」 | |
| TW200819439A (en) | 2-amino-5-substituted pyrimidine inhibitors | |
| CZ20033431A3 (en) | 5-ht receptor ligands and uses thereof | |
| TW201211007A (en) | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | |
| WO2018113694A1 (zh) | 稠环基氮杂环丁基三唑类衍生物、其制备方法及其在医药上的应用 | |
| CN117062804A (zh) | 1,3-取代的环丁基衍生物及其用途 | |
| US6030975A (en) | Carboxylic acid derivatives, their preparation and use in treating cancer | |
| JP7634083B2 (ja) | 新規なピラゾール誘導体 | |
| TW201726651A (zh) | ２，３，４，５－四氫吡啶－６－胺衍生物 | |
| JP2004099598A (ja) | 新規なイソオキサゾール−スルホンアミドエンドセリンアンタゴニスト | |
| CN106749203A (zh) | 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用 | |
| BR112018069105B1 (pt) | Composto de pirimidina, composição e uso do mesmo | |
| CN118742539A (zh) | 杂环类衍生物及其制备方法和用途 | |
| TW200403063A (en) | Novel compounds | |
| HK1230168B (zh) | 经取代的双环二氢嘧啶酮及其作为嗜中性粒细胞弹性蛋白酶活性的抑制剂的用途 | |
| HK1230167B (zh) | 经取代的双环二氢嘧啶酮及其作为嗜中性粒细胞弹性蛋白酶活性的抑制剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200228 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20210105 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210401 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210525 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210618 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6902045 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |